News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Spain’s Zeltia SA Jumps on Ovarian Cancer Drug News
August 7, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Aug 7 (Reuters) - Spanish pharmaceutical firm Zeltia said on Thursday it would seek regulatory approval for the use of its Yondelis drug to treat ovarian cancer after good results from final trials, sending the stock soaring.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
·
2 min read
·
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
·
2 min read
·
Tristan Manalac
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
·
2 min read
·
Tristan Manalac
